PDCD1 and neoplasm: Antibodies targeting the programmed cell death protein 1 (PD-1) are the most widely used ICIs, which work by blocking the binding between PD-1 receptor of T cells and PD-L1 ligand of tumor cells, and restoring the function of T cells that recognizes and eliminates tumor cells (2).